|
1
|
Ostrom QT, Francis SS and Barnholtz-Sloan
JS: Epidemiology of brain and other CNS tumors. Curr Neurol
Neurosci Rep. 21(68)2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hanif F, Muzaffar K, Perveen K, Malhi SM
and Simjee SU: Glioblastoma multiforme: A review of its
epidemiology and pathogenesis through clinical presentation and
treatment. Asian Pac J Cancer Prev. 18(3)2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ostrom QT, Cioffi G, Gittleman H, Patil N,
Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS statistical
report: Primary brain and other central nervous system tumors
diagnosed in the United States in 2012-2016. Neuro Oncol.
21:v1–v100. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ostrom QT, Cote DJ, Ascha M, Kruchko C and
Barnholtz-Sloan JS: Adult Glioma incidence and survival by race or
ethnicity in the United States from 2000 to 2014. JAMA Oncol.
4:1254–1262. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Molinaro AM, Hervey-Jumper S, Morshed RA,
Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A,
Lafontaine M, et al: Association of maximal extent of resection of
Contrast-enhanced and non-contrast-enhanced tumor with survival
within molecular subgroups of patients with newly diagnosed
glioblastoma. JAMA Oncol. 6:495–503. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Buckner JC, Shaw EG, Pugh SL, Chakravarti
A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, et
al: Radiation plus Procarbazine, CCNU, and vincristine in low-grade
glioma. N Engl J Med. 374:1344–1355. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Weller M, van den Bent M, Preusser M, Le
Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven
L, et al: EANO guidelines on the diagnosis and treatment of diffuse
gliomas of adulthood. Nat Rev Clin Oncol. 18:170–186.
2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Overview|Brain tumours (primary) and brain
metastases in over 16s|Guidance|NICE.
|
|
11
|
McBain C, Lawrie TA, Rogozińska E,
Kernohan A, Robinson T and Jefferies S: Treatment options for
progression or recurrence of glioblastoma: A network meta-analysis.
Cochrane Database Syst Rev. 5(CD013579)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lombardi G, Idbaih A, le Rhun E, Preusser
M, Zagonel V and French P: A new landscape for systemic
pharmacotherapy of recurrent glioblastoma? Cancers (Basel). 12:1–4.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Batchelor TT, Mulholland P, Neyns B,
Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S,
Ashby LS, et al: Phase III randomized trial comparing the efficacy
of cediranib as monotherapy, and in combination with lomustine,
versus lomustine alone in patients with recurrent glioblastoma. J
Clin Oncol. 31:3212–3218. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wick W, Gorlia T, Bendszus M, Taphoorn M,
Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al:
Lomustine and bevacizumab in progressive glioblastoma. N Engl J
Med. 377:1954–1963. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Addeo R, Lamberti G, Simonetti G, Iodice
P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M,
Prete SD and Silvani A: Biweekly fotemustine schedule for recurrent
glioblastoma in the elderly: Activity and toxicity assessment of a
multicenter study. CNS Oncol. 8(CNS32)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Røed Skårderud M, Polk A, Kjeldgaard
Vistisen K, Larsen FO and Nielsen DL: Efficacy and safety of
regorafenib in the treatment of metastatic colorectal cancer: A
systematic review. Cancer Treat Rev. 62:61–73. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Martini G, Troiani T, Cardone C, Vitiello
P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo
F, Raucci A, et al: Present and future of metastatic colorectal
cancer treatment: A review of new candidate targets. World J
Gastroenterol. 23:4675–4688. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
de La Fouchardière C: Regorafenib in the
treatment of metastatic colorectal cancer. Future Oncol.
14:2239–2246. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lombardi G, de Salvo GL, Brandes AA, Eoli
M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et
al: Regorafenib compared with lomustine in patients with relapsed
glioblastoma (REGOMA): A multicentre, open-label, randomised,
controlled, phase 2 trial. Lancet Oncol. 20:110–119.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bruno F, Pellerino A, Palmiero R, Bertero
L, Mantovani C, Garbossa D, Soffietti R and Rudà R: Glioblastoma in
the elderly: Review of molecular and therapeutic aspects.
Biomedicines. 10(664)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mason M, Laperriere N, Wick W, Reardon DA,
Malmstrom A, Hovey E, Weller M and Perry JR: Glioblastoma in the
elderly: Making sense of the evidence. Neurooncol Pract. 3:77–86.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Louis DN, Perry A, Wesseling P, Brat DJ,
Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM,
Reifenberger G, et al: The 2021 WHO classification of tumors of the
central nervous system: A summary. Neuro Oncol. 23:1231–1251.
2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bady P, Sciuscio D, Diserens AC, Bloch J,
van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L,
Heppner FL, et al: MGMT methylation analysis of glioblastoma on the
Infinium methylation BeadChip identifies two distinct CpG regions
associated with gene silencing and outcome, yielding a prediction
model for comparisons across datasets, tumor grades, and
CIMP-status. Acta Neuropathol. 124:547–560. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vlassenbroeck I, Califice S, Diserens AC,
Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard
I, Delorenzi M, et al: Validation of real-time methylation-specific
PCR to determine O6-methylguanine-DNA methyltransferase gene
promoter methylation in glioma. J Mol Diagn. 10:332–337.
2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Capper D, Weissert S, Balss J, Habel A,
Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H,
et al: Characterization of R132H mutation-specific IDH1 antibody
binding in brain tumors. Brain Pathol. 20:245–254. 2010.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lombardi G, Caccese M, Padovan M, Cerretti
G, Pintacuda G, Manara R, Di Sarra F and Zagonel V: Regorafenib in
recurrent glioblastoma patients: A large and monocentric real-life
study. Cancers (Basel). 13(4731)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Tzaridis T, Gepfner-Tuma I, Hirsch S,
Skardelly M, Bender B, Paulsen F, Schaub C, Weller J, Schäfer N,
Herrlinger U and Tabatabai G: Regorafenib in advanced high-grade
glioma: A retrospective bicentric analysis. Neuro Oncol.
21:954–955. 2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kebir S, Rauschenbach L, Radbruch A,
Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M,
Forsting M, Sure U, et al: Regorafenib in patients with recurrent
high-grade astrocytoma. J Cancer Res Clin Oncol. 145:1037–1042.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Hegi ME, Diserens A-C, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ohgaki H and Kleihues P: The definition of
primary and secondary glioblastoma. Clin Cancer Res. 19:764–772.
2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Grothey A, van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Santangelo A, Rossato M, Lombardi G,
Benfatto S, Lavezzari D, De Salvo GL, Indraccolo S, Dechecchi MC,
Prandini P, Gambari R, et al: A molecular signature associated with
prolonged survival in Glioblastoma patients treated with
Regorafenib. Neuro Oncol. 23:264–276. 2021.PubMed/NCBI View Article : Google Scholar
|
